Navigation Links
MedImmune's Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
Date:8/23/2007

Native American infants, with an overall incidence and severity of adverse events (AEs) that were similar between the motavizumab and the placebo groups. The mortality rates were not statistically different between groups (0.4 percent in the placebo arm, n=2 and 0.3 percent in the motavizumab arm, n=3) and were not considered to be related to the study drug. As was suggested in the pivotal Phase 3 trial conducted in high-risk, preterm infants, rates of hypersensitivity related skin rashes within two days of dosing were seen in about one percent of treated children in the motavizumab group.

MedImmune's Commitment to RSV Prevention

MedImmune is a world leader in the development of innovative therapeutic biologic products to prevent RSV disease. In 1996, MedImmune launched the first anti-RSV drug, RespiGam(R) (respiratory syncytial virus immune globulin intravenous (human) (RSV-IGIV)), which was a polyclonal antibody administered via four-hour intravenous infusion. In 1998, MedImmune introduced Synagis, which was a significant product improvement as a monthly intramuscular injection for the prevention of severe RSV, as well as being the first MAb to receive U.S. Food and Drug Administration (FDA) approval for an infectious disease. With the development of motavizumab, MedImmune continues to reinforce its commitment to developing anti-RSV products. In a head-to-head comparative Phase 3 trial with Synagis, motavizumab met its primary endpoint of reducing RSV-related hospitalizations in high-risk pediatric patients and met its secondary endpoint of reducing medically attended, outpatient respiratory tract infections in that patient group. MedImmune is also developing a small-molecule product candidate to prevent RSV as well as a vaccine against RSV, both of which are in Phase 1 clinical trials.

About RSV

Each year, up to 125,000 infants in the U.S. are hospitalized with severe RSV infections, the leading cause of lower respiratory tract infections
'/>"/>

SOURCE MedImmune, Inc.
Copyright©2007 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
2. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
3. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
4. Lipitor Reduced the Risk of Coronary Events by Half and Stroke by Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who Experienced a Recent Stroke
5. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
6. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
7. New Analysis of WHI Data Shows Reduced Levels of Coronary Artery Calcification, a Predictor of Cardiovascular Events, in Women aged 50-59 taking Estrogen Therapy
8. Pivotal Phase III Trial Showed Promacta (eltrombopag olamine) Raised Platelet Counts and Reduced Bleeding in Patients With Chronic ITP
9. Preclinical Study Finds Protease Inhibitor-Resistant HIV May Have Reduced Potential to Develop Resistance to Panacos Bevirimat
10. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
11. Data Suggest Cymbalta Reduced Severity of Night Pain in Patients with Diabetic Nerve Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... , May 21, 2013 Ceregene, ... secondary analysis of its double-blind, randomized, controlled Phase ... a gene therapy product designed to deliver the ... analysis identified a more robust response to CERE-120 ... to treatment relative to those diagnosed 10 years ...
(Date:5/21/2013)... LEESBURG, Va. , May 21, 2013 /PRNewswire/ ... than 22,000 pharmacies nationwide, announces today the publication ... Healing America,s Post-Reform Health Care System. The white ... health, reducing costs, and seeks public engagement to ... Personalized Pharmacist Care refers to a range ...
(Date:5/20/2013)... 2013 Landauer, Inc. (NYSE: LDR ... measurement and monitoring, outsourced medical physics services and high ... of Directors declared, at its meeting on May 16, ... share for the third quarter of fiscal 2013.  The ... shareholders of record on June 7, 2013. ...
Breaking Medicine Technology:Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 2Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 3Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 4Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 5RxAlly Releases White Paper on Necessity of Personalized Pharmacist Care 2RxAlly Releases White Paper on Necessity of Personalized Pharmacist Care 3Landauer, Inc. Declares Regular Cash Dividend 2
... M.D., to Moderate Discussion, Following Presentations by Tony Yaksh, Ph.D.; Jerome ... ... JOLLA, Calif., June 25 A Webinar hosted by,TorreyPines Therapeutics, Inc. ... bring together industry experts to discuss the opportunity of treating,chronic pain, ...
... Vical Incorporated,(Nasdaq: VICL ) today announced that ... three-year, $6.0 million grant awarded in,2007, and is ... manufacturing,process with the potential to produce several million ... The RapidResponse(TM) system is designed to allow extremely ...
Cached Medicine Technology:TorreyPines Therapeutics to Host Webinar at 11 a.m. EDT Today on the Opportunity for Treating Chronic Pain, Migraine and Muscle Spasticity Through Inhibition of Neurotransmitter Glutamate 2TorreyPines Therapeutics to Host Webinar at 11 a.m. EDT Today on the Opportunity for Treating Chronic Pain, Migraine and Muscle Spasticity Through Inhibition of Neurotransmitter Glutamate 3TorreyPines Therapeutics to Host Webinar at 11 a.m. EDT Today on the Opportunity for Treating Chronic Pain, Migraine and Muscle Spasticity Through Inhibition of Neurotransmitter Glutamate 4Vical Advances RapidResponse(TM) DNA Vaccine Platform Under $6 Million Grant from NIH 2Vical Advances RapidResponse(TM) DNA Vaccine Platform Under $6 Million Grant from NIH 3Vical Advances RapidResponse(TM) DNA Vaccine Platform Under $6 Million Grant from NIH 4Vical Advances RapidResponse(TM) DNA Vaccine Platform Under $6 Million Grant from NIH 5
(Date:5/21/2013)... Nearly 40 Platinum Supplemental Insurance Sales Representatives ... Los Cabos, Mexico, Feb. 23-March 1, 2013, to help renovate ... The facility serves meals and provides a social outlet for ... , Platinum Vice President, Mike Muench, says that the idea ... , “Platinum got its start selling long-term care insurance ...
(Date:5/21/2013)... May 21, 2013 Dimensional Insight, a ... announced that Western Maryland Health System, a ... The Diver Solution™ (Diver) to help it analyze its ... first customer to purchase Diver through Dimensional Insight’s recently ... Like most hospitals, Western Maryland has massive amounts of ...
(Date:5/21/2013)... Tools4ever, the market leader in Identity & Access ... Password Management (SSRPM) suitable for BYOD. With the latest ... on mobile systems i.e.; laptops, tablets, handheld computers and ... Windows passwords anywhere, anytime. Once the end user has ... then reset his or her own password. , ...
(Date:5/21/2013)... TUESDAY, May 21 (HealthDay News) -- Thousands of ... from the lung condition known as chronic obstructive ... that patients placed on the common antibiotic azithromycin ... due to flare-ups of the disease. "Given ... of such events is critical," said Victoria Richards, ...
(Date:5/21/2013)... ─ Clinical measurement of physical activity appears to ... patients with chronic obstructive pulmonary disease (COPD) will ... study conducted by researchers in Connecticut. The study ... levels of inactivity with an increased incidence of ... of the study will be presented at the ...
Breaking Medicine News(10 mins):Health News:Platinum Supplemental Insurance Gives Back at Casa De Dia, Mexico 2Health News:Platinum Supplemental Insurance Gives Back at Casa De Dia, Mexico 3Health News:Dimensional Insight Announces Western Maryland Health System as First Customer Through Premier Healthcare Alliance 2Health News:Dimensional Insight Announces Western Maryland Health System as First Customer Through Premier Healthcare Alliance 3Health News:Tools4ever’s password reset software ready for BYOD 2Health News:Long-Term Use of Antibiotic May Help Those With COPD 2Health News:Long-Term Use of Antibiotic May Help Those With COPD 3Health News:Exercise levels may predict hospitalizations in COPD population 2
... Dec. 13, Speaker Nancy Pelosi,issued the following statement ... Leader George Mitchell, which found widespread use,of steroids and ... Mitchell Report tells a troubling story of how many ... the fans of our national,pastime by using steroids and ...
... Poll Shows Rural Seniors Want E-Prescribing in Medicare, ... so many issues, promoting electronic prescribing (e-prescribing) in,Medicare ... and Democrats can,agree on. "The Medicare Electronic Medication ... require that Medicare physicians begin to,prescribe electronically, will ...
... The University of Illinois at Chicago College of Nursing has ... people as they transition to the end of life. ... the science of care for people of all ages facing ... funded through a $2.4 million grant from the National Institute ...
... side effects, including heart trouble , , THURSDAY, Dec. 13 ... Andy Pettitte, Houston Astros All-Star shortstop Miguel Tejada and ... players cited in a highly anticipated report into the ... , The report climaxed a 20-month probe by former ...
... 13 The Quantum Group,Inc. (Amex: QGP, QGP.U) ... its registered public offering, raising $13.2 million in,gross ... initiated trading,on the American Stock Exchange (AMEX) of ... "QGP.U." In addition, Quantum common shares,formerly traded on ...
... Dec. 13 Repligen Corporation,(Nasdaq: RGEN ) ... has been,elected to its Board of Directors. Dr. ... and regulatory expertise in the,development of therapeutics for ... very pleased to welcome an executive with Earl,s ...
Cached Medicine News:Health News:One Thing Washington Can Agree On: Time for E-Prescribing in Medicare 2Health News:One Thing Washington Can Agree On: Time for E-Prescribing in Medicare 3Health News:New UIC center to study end-of-life transition 2Health News:New UIC center to study end-of-life transition 3Health News:Report Finds 'Widespread Steroid Use in Baseball' 2Health News:Report Finds 'Widespread Steroid Use in Baseball' 3Health News:The Quantum Group, Inc. Completes $13.2 Million Public Offering and Initiates Trading on the American Stock Exchange Under Symbol 'QGP' 2Health News:The Quantum Group, Inc. Completes $13.2 Million Public Offering and Initiates Trading on the American Stock Exchange Under Symbol 'QGP' 3Health News:Repligen Elects Earl Henry, M.D. to the Board of Directors 2Health News:Repligen Elects Earl Henry, M.D. to the Board of Directors 3
Storage temperature: 15 - 30C, linearity: 0 - 20 mg/dL, expected value: male: 3.0 - 7.0 mg/dL and female: 2.2 - 6.2 mg/dL. Available with calibrator and number of tests 125....
For the quantitative determination of Uric Acid in serum. Linearity: 25 mg/dl....
... for small and medium volume laboratories, as ... System offers the speed, simplicity and flexibility ... Compact yet powerful, the Elecsys 1010 system ... response assays to routine testing without sacrificing ...
Sample throughput of up to 80 tests per hour (4 modules). Low maintenance requirements. Continuous random access. 25 - 100 channels on board. 1008 tests or 6 hours of walkaway operation....
Medicine Products: